Posts for Replimune Group, Inc. ($REPL)

Showing 1 - 2 of 2 Posts

$REPL

•

Form 10-Q

•

2025-02-12

Last updated: 3 months ago

Replimune Group Q4 2024 Financial Report: Hold Recommendation Amidst Losses

Explore Replimune Group, Inc.'s Q4 2024 financial report. Key insights on losses, cash management, and clinical trial outcomes suggest a 'Hold' stock recommendation.

Biotechnology Oncolytic Immunotherapy Clinical Trials Investment Strategy Cancer Treatment

$REPL

•

Form 8-K

•

2025-02-12

Last updated: 3 months ago

Replimune Group, Inc. 8-K Report: Financial Insights as of February 12, 2025

Explore Replimune Group, Inc.'s 8-K filing detailing financial data and updates as of February 12, 2025. Key insights for investors and stakeholders.

Replimune Group biotechnology NASDAQ REPL financial reporting investor relations